Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 18, 1997, Pages 2415-2420

  Connolly, Cleo J C ^a   Hamby, James M ^a   Schroeder, Mel C ^a   Barvian, Mark ^a   Lu, Gina H ^a   Panek, Robert L ^a   Amar, Aneesa ^a   Shen, Cindy ^a   Kraker, Alan J ^a   Fry, David W ^a   Klohs, Wayne D ^a   Doherty, Annette M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOENZYME; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE;

ARTICLE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION;

EID: 0030773973     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00445-9     Document Type: Article

References (25)

1. Blankley, C. J.; Doherty, A. M.; Hamby, J. M.; Panek, R. L.; Schroeder, M. C.; Showalter, H. D. H.; Connolly, C. WO PCT Appl. 9615128, 1996; Chem. Abstr. 1995, 125, 114688.
2. Fry, D. W.; Bridges, A. J. Curr. Opin. Biotech. 1995, 6, 662.
3. Bornfeldt, K. E. Trends Cardiovasc. Med. 1996, 6, 143.
4. Reidy, M. A.; Bendeck, M. P. In Coronary Restenosis: From Genetics to Therapeutics; Feuerstein, G., Ed.; Dekker: New York, 1997, Vol. 28, pp 55-67.
5. Fry, D. W. Expert Opin. Invest. Drugs 1994, 3, 577.
6. Klein, S.; Roghani, M.; Rifkin, D. B. EXS 1997, 79, 159.
7. Brunton, V. G.; Ozanne, B. W.; Paraskeva, C.; Frame, M. C. Oncogene 1997, 14 , 283.
8. Verbeek, B. S.; Vroom, T. M.; Adriaansen-Slot, S. S.; Ottenhoff-Kalff, A. E.; Geertzema, J. G. N.; Hennipman, A.; Rijksen, G. J. Pathol. 1996, 180 , 383.
9. Connolly, C. J. C.; Hamby, J. M.; Schroeder, M.C.; Lu, G. H.; Panek, R. L.; Amar, A.; Shen, C.; Kraker, A. J.; Doherty, A. M. 211th ACS National Meeting: New Orleans, LA, March 1996, MEDI 193.
10. 50 values reported for kinase inhibition represent the means of at least two separate experiments each done in triplicate with typical variations of less than 30% between replicate values.
11. Garfinkel, S.; Hu, X.; Prudovsky, I. A.; McMahon, G. A.; Kapnik, E. M.; McDowell, S. D.; Maciag, T. J. Cell Biol. 1996, 134, 783.
12. 2 incubator after which concentrations of compounds were added to wells and cells were incubated with the indicated compounds for 4 days. The effect of the compounds was determined with sulphorhodamine B as previously described in the following reference: Skehan, P.; Stoneng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.; Bokesch, H.; Kenney, S.; Boyd, M. J. Natl. Cancer Inst. 1990, 82, 1107.
13. Bennett, L. R.; Blankley, C. J.; Fleming, R. W.; Smith, R. D.; Tessman, D. K. J. Med. Chem. 1981, 24, 382.
14. Blankley, C. J.; Boschelli, D. H.; Doherty, A. M.; Hamby, J. M.; Klutchko, S.; Panek, R. L. WO PCT Appl. 9634867, 1996; Chem. Abstr. 1996, 126, 59965.
15. Gossett, L. S.; Shih, C. J. WO PCT Appl. 9509845, 1995; Chem. Abstr. 1995, 123, 286711.
16. Stuart, A.; Paterson, T.; Roth, B.; Aig, E. J. Med. Chem. 1983, 26, 667.
17. Boyer, J.; Bruylants, A. Bull. Soc. Chim. Fr. 1958, 453.
18. (a) PDGFr-TK/FGFr-TK inhibition assay conditions: Escobedo, J. A.; Keating, M. T.; Ives, H. E. J. Biol. Chem. 1988, 263, 1482.
19. (b) Lu, G. H.; Connors, R.; Panek, R.; FASEB Meeting, Anaheim, CA, Spring 1994, Abstract 253.
20. C-Src tyrosine kinase inhibition assay conditions: Thompson, A. M.; Fry, D. W.; Kraker, A. J.; Denny, W. A.; J. Med. Chem. 1994, 37, 21.
21. MAPK inhibition assay conditions : Alessi, D. R.; Cuenda, A.; Cohen, P.; Dudley, D. T.; Saltiel, A. R. J. Biol. Chem. 1995, 270, 27489.
22. EGFr tyrosine kinase inhibition assay conditions: Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambroso, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. Science 1994, 265, 1093.
23. For insulin receptor (InsR) tyrosine kinase inhibition assay conditions see: Fry, D. W.; Kraker, A. J.; Connors, R. C.; Elliot, W. L.; Nelson, J. M.; Showalter, H. D. H.; Leopold, W. R. Anti-Cancer Drug Des. 1994, 9, 331.
24. Protein kinase C (PKC) inhibition assay conditions: Martiny-Baron, G.; Kazanietz, M. G.; Mischak, H.; Blumberg, P. M.; Kochs, G.; Hug, H.; Marme, D.; Schachtele, C. J. Biol. Chem. 1993, 268, 9194.
25. 32P incorporation determined with a β-plate counter.